About this trial
Background: Uricemia dramatically rises with the stage of chronic kidney disease (CKD) and correlates with its mortality. Hemodialysis (HD) being the most used treatment at the end stage kidney disease in Sohag governorate , we sought to evaluate its efficacy on the clearance of uric acid (UAc) when used alone and twice per week.
Methods: A cross-sectional study of all consenting patients with CKD stage 5 recruited at random during hemodialysis sessions at hemodialysis unit in Sohag university hospital from July to December 2025. We collected socio-demographic data, relevant clinical information, hemodialysis related variables, and measured serum uric acid (SUA) levels before and after the dialysis to assess the uric acid clearance. A clearance between 65 and 80% and above 80% was considered as low and good efficacy of hemodialysis respectively
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
We included all consenting adults aged 18 or older, on maintenance hemodialysis for at least 3 consecutive months receiving 2 to 3 sessions weekly
Disqualifiers
Patients aged < 18 years old .
Patients on recent hemodialysis less than 3 months.
We excluded patients who were on Uric acid lowering therapy (UALT).
Patients received less than 4 hours of hemodialysis and those who had emergency dialysis.
Trial population
Hemodialysis patients
Trial design
Case-only
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
study of serum uric acid level in hemodialysis patients
milligrams per deciliter (mg/dL)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.